Megadose of Hydroxocobalamin for the Treatment of Pernicious Anemia
Overview
Demonstrate the effectiveness of a single dose of a multivitamin complex for the treatment of megaloblastic anemia
Full Title of Study: “Megadose of Hydroxocobalamin (Vitamin B12) for the Treatment of Pernicious Anemia”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: December 1, 2018
Detailed Description
The investigators will administrate a single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg. To assess response to treatment, a complete blood count (CBC) will be performed weekly during the first month of treatment, after the first month a CBC will be taken monthly for 6 months. Also to confirm the diagnosis and assess response the investigators will measure levels of methylmalonic acid, homocysteine, and hydroxocobalamin at the beginning of the study, 3 and 6 months.
Interventions
- Drug: Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
- Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.
Arms, Groups and Cohorts
- Experimental: Megadose multivitamin complex
- Intramuscular injection of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
Clinical Trial Outcome Measures
Primary Measures
- Hematologic response
- Time Frame: 2 month
- Normalization of complete blood count (CBC).
- Duration of hematologic response
- Time Frame: 6 months
- Duration of response (months) after the administration of megadose of hydroxocobalamin
Secondary Measures
- Measure levels of hydroxocobalamin
- Time Frame: Basal, three and six months
- Measure levels of methylmalonic acid.
- Time Frame: Basal, three and six months
- Measure levels of homocysteine.
- Time Frame: Basal, three and six months
- Evaluate time to hematologic response
- Time Frame: 1 month
- Time to response after the administration of 10,000mcg hydroxocobalamin
Participating in This Clinical Trial
Inclusion Criteria
Age >18, All sex Clinical suspicious of megaloblastic anemia ( cytopenias and macrocytosis (CBC), hypersegmented neutrophils and elevated lactate dehydrogenase) Patients must sign an informed consent indicating that they are aware of the investigational nature of this study - Exclusion Criteria:
Administration of hydroxocobalamin in the three years before enrollment Patients with active, uncontrolled psychiatric disorders Severe neurologic deficit Known hematologic malignancy Known coagulation disorder that contraindicates intramuscular injection End-stage kidney disease (GFR <15ml/min) Chronic liver disease (Child-Pugh B or C) Pregnant patients Known infection of Hepatitis B or C and HIV Diagnosis of myelodysplastic syndrome -
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 90 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
- Provider of Information About this Clinical Study
- Principal Investigator: David Gomez Almaguer, Principal Investigator / Head of Hematology Department/MD – Hospital Universitario Dr. Jose E. Gonzalez
- Overall Official(s)
- David Gómez Almaguer, MD, Study Chair, Hospital Universitario Dr. José Eleuterio González
Citations Reporting on Results
Sanz-Cuesta T, Gonzalez-Escobar P, Riesgo-Fuertes R, Garrido-Elustondo S, del Cura-Gonzalez I, Martin-Fernandez J, Escortell-Mayor E, Rodriguez-Salvanes F, Garcia-Solano M, Gonzalez-Gonzalez R, Martin-de la Sierra-San Agustin MA, Olmedo-Luceron C, Sevillano Palmero ML, Mateo-Ruiz C, Medina-Bustillo B, Valdivia-Perez A, Garcia-de Blas-Gonzalez F, Marino-Suarez JE, Rodriguez-Barrientos R, Ariza-Cardiel G, Cabello-Ballesteros LM, Polentinos-Castro E, Rico-Blazquez M, Rodriguez-Monje MT, Soto-Diaz S, Martin-Iglesias S, Rodriguez-Gonzalez R, Breton-Lesmes I, Vicente-Herrero M, Sanchez-Diaz J, Gomez-Gascon T, Drake-Canela M, Asunsolo-del Barco A; OB12 Group. Oral versus intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency: a pragmatic, randomised, multicentre, non-inferiority clinical trial undertaken in the primary healthcare setting (Project OB12). BMC Public Health. 2012 May 31;12:394. doi: 10.1186/1471-2458-12-394.
Stabler SP. Vitamin B12 deficiency. N Engl J Med. 2013 May 23;368(21):2041-2. doi: 10.1056/NEJMc1304350. No abstract available.
Green R. Vitamin B12 deficiency from the perspective of a practicing hematologist. Blood. 2017 May 11;129(19):2603-2611. doi: 10.1182/blood-2016-10-569186. Epub 2017 Mar 30.
Sharabi A, Cohen E, Sulkes J, Garty M. Replacement therapy for vitamin B12 deficiency: comparison between the sublingual and oral route. Br J Clin Pharmacol. 2003 Dec;56(6):635-8. doi: 10.1046/j.1365-2125.2003.01907.x.
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.